Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ABVN Phase 2 - EDS Wearable Device

NCT: NCT07856459 · COMPLETED

NCT IDNCT07856459
StatusCOMPLETED
Start Date2024-07-30
Completion2025-10-24
SponsorIndiana University (OTHER)
First posted
Last updated

Brief Summary

The vagus nerve is a nerve that controls many bodily functions, including stomach function. Investigators hope that electrically stimulating the nerve around the external ear will also stimulate the internal vagus nerve. If it does, then investigators hope that this may lead to additional treatment options for patients with nausea and vomiting and disordered stomach function. The overall purpose of the ABVN Phase 2 grant is to expand on previous work evaluating the effects of noninvasive stimulation on vagal nerve function. This will be accomplished through several independent, but related, studies. In this study, investigators will evaluate autonomic responses in Ehlers-Danlos Syndrome patients and healthy participants during transcutaneous electrical stimulation of the vagus nerve and during normal daily activities.

Frequently Asked Questions

What is ABVN Phase 2 - EDS Wearable Device?

ABVN Phase 2 - EDS Wearable Device is a clinical trial registered under NCT07856459. Current status: COMPLETED.

What is the status of NCT07856459?

The current status of NCT07856459 (ABVN Phase 2 - EDS Wearable Device) is: COMPLETED.

When did ABVN Phase 2 - EDS Wearable Device start?

ABVN Phase 2 - EDS Wearable Device started on 2024-07-30.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑